Cilostazol induces mitochondrial fatty acid β-oxidation in C2C12 myotubes

Biochemical and Biophysical Research Communications

Volumn 447, Issue 3, 2014, Pages 441-445

  Wang, Bo ^a   Zhu, Liping ^b   Sui, Shaohua ^c   Sun, Caixia ^a   Jiang, Haiping ^a   Ren, Donghui ^a  

^a YANTAISHAN HOSPITAL   (China)

^b Zhucheng People's Hospital   (China)

^c Department of Endocrinology YanTai Development Zone Hospital   (China)

Author keywords

Cilostazol; Fatty acid oxidation; Metabolic diseases; PGC 1

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE I; CD36 ANTIGEN; CILOSTAZOL; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ESTROGEN RELATED RECEPTOR ALPHA; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; MITOCHONDRIAL PROTEIN; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NUCLEAR RECEPTOR NR4A3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHODIESTERASE III; PROTEIN ACO; SMALL INTERFERING RNA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GENE TARGETING; INTERMITTENT CLAUDICATION; MITOCHONDRION; MOUSE; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

CILOSTAZOL; FATTY ACID Β-OXIDATION; METABOLIC DISEASES; PGC-1Α;

ANIMALS; ANTIGENS, CD36; CADHERINS; CARNITINE O-PALMITOYLTRANSFERASE; CELL LINE; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; FATTY ACIDS; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; IRON REGULATORY PROTEIN 1; ISOQUINOLINES; MITOCHONDRIA; MUSCLE FIBERS, SKELETAL; OXIDATION-REDUCTION; PROTEIN KINASE INHIBITORS; RECEPTORS, ESTROGEN; RNA, SMALL INTERFERING; SULFONAMIDES; TETRAZOLES; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 84899989641     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.04.028     Document Type: Article

References (24)

1. Nagao K., Yanagita T. Medium-chain fatty acids: functional lipids for the prevention and treatment of the metabolic syndrome. Pharmacol. Res. 2010, 61:208-212.
2. Garbarino J., Sturley S.L. Saturated with fat: new perspectives on lipotoxicity. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12:110-116.
3. Muoio D.M., Newgard C.B. Fatty acid oxidation and insulin action: when less is more. Diabetes 2008, 57:1455-1456.
4. Stevens J.W., Simpson E., Harnan S., et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br. J. Surg. 2012, 99:1630-1638.
5. Sudo T., Tachibana K., Toga K., et al. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem. Pharmacol. 2000, 59:347-356.
6. Grossmann C., Ruhs S., Seiferth A., et al. Interaction between mineralocorticoid receptor and cAMP/CREB signaling. Steroids 2010, 75:539-543.
7. Herzig S., Hedrick S., Morantte I., et al. CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma. Nature 2003, 426:190-193.
8. Liu C., Lin J.D. PGC-1 coactivators in the control of energy metabolism. Acta Biochim. Biophys. Sin. (Shanghai) 2011, 43:248-257.
9. Muoio D.M., Way J.M., Tanner C.J., et al. Peroxisome proliferator-activated receptor-regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes 2002, 51:901-909.
10. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957, 226:497-509.
11. Zhou G., Hamik A., Nayak L., et al. Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice. J. Clin. Invest. 2012, 122:4727-4731.
12. Shi H., Sheng B., Zhang F., et al. Kruppel-like factor 2 protects against ischemic stroke by regulating endothelial blood brain barrier function. Am. J. Physiol. Heart Circ. Physiol. 2013, 304:H796-H805.
13. Holloszy J.O. Regulation by exercise of skeletal muscle content of mitochondria and GLUT4. J. Physiol. Pharmacol. 2008, 59(Suppl. 7):5-18.
14. Kimura Y., Tani T., Kanbe T., et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985, 35:1144-1149.
15. Lonard D.M., O'Malley B.W. The expanding cosmos of nuclear receptor coactivators. Cell 2006, 125:411-414.
16. Nakamura N., Osawa H., Yamabe H., et al. Effects of cilostazol on lipid and fatty acid metabolism. Clin. Exp. Med. 2005, 4:170-173.
17. Takazakura E., Osawa K., Hamamatsu K. Effect of cilostazol (Pletaal) on serum lipid levels in diabetic patients. Jpn. Pharmacol. Ther. 1989, 17:311-315.
18. Elam M.B., Heckman J., Crouse JR., et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1942-1947.
19. Nakamura N., Hamazaki T., Johkaji H., et al. Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease. Clin. Exp. Med. 2003, 2:180-184.
20. Tani T., Uehara K., Sudo T., et al. Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. Atherosclerosis 2000, 152:299-305.
21. Motobayashi T., Morita T., Ueki H. Involvement of the rapid increase in cAMP content in the vanadate-stimulates release of lipoproteins lipase activity from rat fat pads. Biol. Pharm. Bull. 1996, 19:1412-1416.
22. Sheng B., Wang X., Su B., et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J. Neurochem. 2012, 120:419-429.
23. Koves T.R., Li P., An J., et al. Peroxisome proliferator-activated receptor- co-activator 1-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. J. Biol. Chem. 2005, 280:33588-33598.
24. Zuo L., Li Q., Sun B., et al. Cilostazol promotes mitochondrial biogenesis in human umbilical vein endothelial cells through activating the expression of PGC-1α. Biochem. Biophys. Res. Commun. 2013, 433:52-57.